Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).


Read more

Related posts

Leave a Reply